不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
携带 CARS1-ALK 融合的炎性肌纤维母细胞瘤患者的 ALK 抑制治疗
英文原题：ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion.
查看英文原题
ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
炎性肌纤维母细胞瘤（IMT）是一种罕见疾病，主要影响年轻个体，常累及腹部、盆腔或肺部。约50%的IMT存在间变性淋巴瘤激酶（ALK）基因重排，使ALK抑制剂成为可行的治疗选择。我们报告一例40岁女性转移性IMT患者，携带CARS1-ALK融合。初始化疗失败，但通过韩国精准医学网络研究组基于晚期实体瘤基因组改变指导治疗的分子谱分析研究（KOSMOS）-II研究，接受alectinib靶向治疗后，肿瘤显著消退，并持续获得19个月的持久临床改善。本病例凸显了精准医学的重要性，并提示对于具有可操作基因组改变的罕见癌症，应重新评估超适应症使用靶向药物。
展开英文摘要原文
Inflammatory myofibroblastic tumor (IMT) is a rare entity, primarily affecting young individuals, often involving the abdomen, pelvis, or lung. Approximately 50% of IMTs harbor anaplastic lymphoma kinase (ALK) gene rearrangements, making ALK inhibitors a viable treatment.
We report a case of a 40-year-old female with metastatic IMT harboring a CARS1-ALK fusion. Initial chemotherapy failed, but targeted therapy with alectinib through the KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study led to significant tumor regression and ongoing, durable clinical improvement of 19 months.
This case highlights the importance of precision medicine and raises the reappraisal of targeted agents outside of approved indications for rare cancers with actionable genomic alterations.
论文信息
- 作者
- Choi S、Kim M、Kim S、Park T、Kwak Y、Bae JM、Yun H、Kim JH
- 第一作者单位
- Department of Genomic Medicine, Seoul National University Hospital, Seoul, Korea.South Korea
- 通讯作者单位
- Department of Internal Medicine, Department of Genomic Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.South Korea
- 文献类型
- 病例报告
- 期刊
- Cancer research and treatment2025 Jul
- 原文标识
- PubMed 39701088 · DOI 10.4143/crt.2024.1184
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →